Venue: Baltimore Marriott Waterfront

Location: Baltimore, Maryland, United States

Event Date/Time: Jun 02, 2003 End Date/Time: Jun 06, 2003
Registration Date: Apr 18, 2003
Early Registration Date: Mar 07, 2003
Abstract Submission Date: Apr 24, 2003
Paper Submission Date: Apr 24, 2003
Report as Spam


The frontier of gene quantification has moved from a focus on the quantitation of a few genes in a few samples, with exquisite precision and/or accuracy, to a focus on the quantitation of tens to hundreds of genes in thousands to tens of thousands of samples with adequate precision. One of the key aspects of the microarray revolution is that in many cases the analysis of thousands of genes leads to the discovery of significantly smaller sets of genes that provide essential information about their biological systems. The new challenge is to use this preliminary, yet essential, information to perform in-depth quantitative analysis of gene networks. New high-throughput technologies (low-density chips and multiplex PCR approaches) address these new needs. Progress in bioinformatics (specifically in data mining) is leading to new understanding of the value of quantitative gene expression analysis for the identification and validation of better therapeutic targets as well as the design of powerful diagnostic assays. Moving from research laboratories into clinical use requires not just innovation but validation and robust industrialization of these new technologies. Expanded and more cost-effective access to the powerful technology of real-time PCR and other quantitative techniques has already led to a number of innovations in preclinical and clinical research. But choosing the most appropriate tools and data analysis systems for specific applications still remains a challenge.
Nucleic acid amplification and detection have become the most widely used technique for conducting biological research. Like the genetic material being exponentially amplified utilization has exploded to an increasing range of applications including molecular biology, environmental science, forensic science, medical science, biotechnology, microbiology, the food industry, diagnostic science, epidemiology, genetics, gene cloning, and more. Microarray development continues to drive these discoveries. New technical developments that improve the performance of nucleic acid amplification and detection, as well as interesting examples of how these techniques are used, are the emphases of this meeting.
Scientific Advisors
Dr. Stanley Abramowitz, Advanced Technology Group
Dr. Michael Egholm, Molecular Staging, Inc.
Mr. Shaun Lonergan, NimbleGen Systems

Kick-off Keynote
Overcoming the PCR Obstacle to High-Throughput DNA Analysis
Dr. Charles R. Cantor, Sequenom, Inc.

Sample Preparation
Dr. Kimimichi Obata, Precision System Science Europe GmbH
Dr. Martin Gilar, Life Sciences Chemistry, Waters Corporation
Dr. Sheng-Guo Fang, Zhejian University
Dr. William C. Okulicz, University of Massachusetts Medical School

Primers, Probes, and Detection
Dr. Quin Chou, BioSource International
Dr. Klaus-Peter Stengele, Chemogenix
Dr. George E. Fox, Professor, University of Houston
Dr. Yingfu Li, McMaster University
Dr. Todd Peterson, Genicon Sciences Corporation
Dr. Y. Paul Bao, Nanosphere Inc.

Dr. John P. Langmore, Rubicon Genomics, Inc.
Dr. Ie-Ming Shih, Johns Hopkins School of Medicine
Dr. Michael Egholm
Dr. G. Mike Makrigiorgos, Dana-Farber Cancer Institute and Harvard Medical School
Dr. James R. Prudent, EraGen Biosciences, Inc.
Dr. Chiara Mazzanti, National Institutes of Health
Dr. Bruce Seligmann, High Throughput Genomics
Dr. Michael Herrler, NuGEN Technologies, Inc.
Dr. Ren Y. Xu, Amgen Inc.
Dr. Beverly A. Brown, Linden Bioscience


700 Aliceanna Street
United States

Additional Information

Life-science labs today face enormous challenges of: Engineering new technologies to expedite discovery research Moving research advances into the clinic Ramping up molecular technologies for high throughput, without sacrificing reliability and robustness